MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.63
-0.48
-3.96%
After Hours: 11.63 0 0.00% 16:00 09/23 EDT
OPEN
12.13
PREV CLOSE
12.11
HIGH
12.26
LOW
11.53
VOLUME
785.97K
TURNOVER
--
52 WEEK HIGH
26.26
52 WEEK LOW
10.22
MARKET CAP
540.96M
P/E (TTM)
-2.6324
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that its sterile
Business Wire · 09/15 11:45
American Eagle Outfitters Promotes Aerie Global Brand President Jennifer Foyle to Chief Creative Officer
In her expanded role, Foyle will oversee merchandising, design and marketing for both the American Eagle and Aerie brands.
WWD · 09/09 12:45
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company
Business Wire · 09/08 11:30
Why Is Aerie (AERI) Down 3.6% Since Last Earnings Report?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 16:31
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): When Will It Breakeven?
We feel now is a pretty good time to analyse Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) business as it appears the...
Simply Wall St. · 08/21 14:01
New Strong Sell Stocks for August 10th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Zacks · 08/10 14:01
Citigroup Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $32
Citigroup maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Buy and lowers the price target from $38 to $32.
Benzinga · 08/10 10:50
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
Zacks · 08/07 14:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AERI. Analyze the recent business situations of Aerie Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AERI stock price target is 28.54 with a high estimate of 50.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 254
Institutional Holdings: 62.10M
% Owned: 133.50%
Shares Outstanding: 46.51M
TypeInstitutionsShares
Increased
54
5.57M
New
54
1.04M
Decreased
55
12.29M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Director
Vicente Anido
President/Chief Operating Officer
Thomas Mitro
Co-Founder/Chief Scientific Officer
Casey Kopczynski
Chief Financial Officer/Treasurer/Secretary
Richard Rubino
General Counsel/Secretary
John LaRocca
Finance Director
Amine Sinmazisik
Vice President - Finance
Christopher Staten
Director of Marketing
Nina Ohara
Vice President
Michelle Senchyna
Other
David Hollander
Lead Director/Independent Director
Benjamin McGraw
Director
Peter McDonnell
Independent Director
Gerald Cagle
Independent Director
Richard Croarkin
Independent Director
Mechiel Du Toit
Independent Director
David Gryska
Independent Director
Michael Du Toit
Independent Director
Julie McHugh
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AERI
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.